Use of enrofloxacin in the treatment of canine brucellosis in a dog kennel (clinical trial).
To date, no totally effective antibiotic for the eradication of canine brucellosis has been found. The purpose of this study was to evaluate the efficacy of enrofloxacin in a kennel infected with Brucella canis. Twelve dogs, 2 males and 10 females (including 1 in estrus, 3 pregnant, and 6 in anestrus) infected with B. canis were given 5 mg/kg of enrofloxacin orally every 12 h for 30 days. Females received additional courses of enrofloxacin during the estral and luteal phases of the subsequent cycles (0-2 cycles). They were repeatedly mated by infected males. A serological follow-up was carried out for 38 months. The clinical, serological and bacteriological findings were recorded. In a trial carried out 14 months after the beginning of this study, all dogs were negative on the Rapid Slide Agglutination Test (RSAT). No abortions were observed. All mated female dogs conceived and gave birth to healthy puppies. Cultures of postpartum vaginal discharges (lochia) were negative for B. canis. Similar to other treatments, although enrofloxacin was not completely efficacious in treating canine brucellosis, it maintained fertility and avoided the recurrence of abortions, transmission of the disease to the puppies and dissemination of microorganisms during parturition. We inferred that enrofloxacin could be used as an alternative drug for the treatment of canine brucellosis.
Wanke
M M
MM
Faculty of Veterinary Science, University of Buenos Aires, Theriogenology, Chorroarin 280 (1427), Buenos Aires, Argentina. wanke@fvet.uba.ar
Delpino
M V
MV
Baldi
P C
PC
D000372:Agglutination Tests / Q000662:veterinary; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood; D041002:Brucella canis / Q000254:growth & development* / Q000276:immunology / Q000302:isolation & purification; D002006:Brucellosis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology*; D004285:Dogs; D000077422:Enrofloxacin; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005500:Follow-Up Studies; D008297:Male; D011247:Pregnancy
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D024841:Fluoroquinolones; D000077422:Enrofloxacin